Education
About Us
Working with TipRanks
Follow Us
Inflarx N.V. (IFRX)
:IFRX
IFRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.71 - $2.82
Previous CloseN/A
Volume66.97K
Average Volume (3M)597.25K
Market Cap
$105.40M
Enterprise Value-$2.12M
Total Cash (Recent Filing)$48.00M
Total Debt (Recent Filing)$599.11K
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Oct 30, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding67,133,270
10 Day Avg. Volume1,360,766
30 Day Avg. Volume597,252
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-13.00
Enterprise Value/Gross Profit0.42
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$4.00Price Target Upside142.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceInflaRx boasts a commercial asset and strong cash balance providing runway into 2027, suggesting the stock is undervalued and has significant potential upside.
Product PotentialINF904's therapeutic and biochemical properties indicate it could be a 'pipeline in a pill' with broad applicability in a wide range of indications.
Strategic ShiftResources will be focused on INF904 in HS and CSU, with a positive outlook on these programs.
Bears Say
Clinical Trial ChallengesFollowing the recommendation to stop the Ph.3 trial for vilobelimab in pyoderma gangrenosum due to futility, the focus has shifted.
Development DiscontinuationInflaRx is discontinuing the Phase 3 trial testing vilobelimab for pyoderma gangrenosum based on an unblinded data review recommending stopping due to futility.
Enrollment DelaysData from the Phase 2a basket study testing INF904 in chronic spontaneous urticaria and hidradenitis suppurativa are now expected by the end of September to early November, which is a delay from the prior guidance.
InflaRx News
IFRX FAQ
What was Inflarx N.V.’s price range in the past 12 months?
Inflarx N.V. lowest stock price was $0.71 and its highest was $2.81 in the past 12 months.
What is Inflarx N.V.’s market cap?
Inflarx N.V.’s market cap is $105.40M.
When is Inflarx N.V.’s upcoming earnings report date?
Inflarx N.V.’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.
How were Inflarx N.V.’s earnings last quarter?
Inflarx N.V. released its earnings results on Aug 07, 2025. The company reported -$0.246 earnings per share for the quarter, the consensus estimate of -$0.246 by $0.
Is Inflarx N.V. overvalued?
According to Wall Street analysts Inflarx N.V.’s price is currently Undervalued.
Does Inflarx N.V. pay dividends?
Inflarx N.V. does not currently pay dividends.
What is Inflarx N.V.’s EPS estimate?
Inflarx N.V.’s EPS estimate is -0.18.
How many shares outstanding does Inflarx N.V. have?
Inflarx N.V. has 67,133,270 shares outstanding.
What happened to Inflarx N.V.’s price movement after its last earnings report?
Inflarx N.V. reported an EPS of -$0.246 in its last earnings report, expectations of -$0.246. Following the earnings report the stock price went down -2.381%.
Which hedge fund is a major shareholder of Inflarx N.V.?
Currently, no hedge funds are holding shares in IFRX
InflaRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (142.42% Upside)
$4.00 (142.42% Upside)
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.09%
12-Months-Change
Fundamentals
Return on Equity
-62.38%
Trailing 12-Months
Asset Growth
-13.54%
Trailing 12-Months
Company Description
Inflarx N.V.
InflaRx (IFRX) is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. The company specializes in monoclonal antibodies targeting the complement system, which plays a critical role in immune response and inflammation. InflaRx's lead product candidate, IFX-1, is designed to treat conditions such as hidradenitis suppurativa and other severe inflammatory diseases, positioning the company at the intersection of immunology and biotherapeutics.
IFRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(142.42% Upside)
Technical Analysis
VistaGen Therapeutics
―
Clearside Biomedical
―
Renovaro Biosciences
―
Cabaletta Bio
―
Jasper Therapeutics
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
22.60% Other Institutional Investors
77.33% Public Companies and
Individual Investors